Advanced Medical Solutions (AIM:AMS) FDA approval enhances the appeal
The surgical and advanced woundcare company and one of AIM’s star performers has announced that the FDA has approved two new product claims for the Group’s product. The news moved the shares up another leg to new highs.
The FDA has approved two new product claims for the Group’s octyl formulation product, LiquiBand Exceed™ giving it a competitive advantage in the topical skin adhesive market.
The two new claims include the use of a single device to cover wounds of up to 30cm, as well as a single device being suitable for intraoperative reuse for up to 90 minutes on a single patient. Both claims are unique FDA approved claims for the US Topical Skin Adhesive Market.
Following testing, LiquiBand® Exceed™ was found to deliver best in class yield to support coverage up to 30cm of wound length, twice the amount advertised by market leading topical skin adhesive products.
This is yet another example a high quality AIM stock that is continuing to deliver highly positive news.
The valuation looks rich but this business addresses a huge market and has delivered handsomely over the past few years.